Vireo Growth (VREOF) Depreciation & Amortization - Total (2020 - 2026)
Vireo Growth's (VREOF) quarterly Depreciation & Amortization - Total came in at $1.1 million in Q1 2026, up 1000.0% year-on-year from $100000.0 in Q1 2025, and down 89.34% quarter-over-quarter from $10.3 million in Q4 2025.
Vireo Growth (VREOF) Depreciation & Amortization - Total (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Depreciation & Amortization - Total across 7 years of filings, most recently posting $1.1 million for Q1 2026.
- Depreciation & Amortization - Total for Q1 2026 came in at $1.1 million, up 1000.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 million (up 3772.97% YoY), and the FY2025 annual result was $11.3 million, up 3773.53% from the prior year.
- Depreciation & Amortization - Total came in at $1.1 million for Q1 2026 at Vireo Growth, down from $10.3 million in the prior quarter.
- In the past five years, Depreciation & Amortization - Total ranged from a high of $10.3 million in Q4 2025 to a low of $69931.0 in Q4 2024.
- The 5-year median for Depreciation & Amortization - Total is $156096.0 (2022), against an average of $816247.9.
- Across the five-year window, Depreciation & Amortization - Total plunged 53.89% in 2024 and surged 14657.85% in 2025, its largest moves.
- Vireo Growth's Depreciation & Amortization - Total stood at $165913.0 in 2022, then plunged by 44.05% to $92827.0 in 2023, then retreated by 24.67% to $69931.0 in 2024, then soared by 14657.85% to $10.3 million in 2025, then sank by 89.34% to $1.1 million in 2026.
- The last three Depreciation & Amortization - Total figures came in at $1.1 million (Q1 2026), $10.3 million (Q4 2025), and $552589.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | - |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | - |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | - |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | - |
| 10 | Vireo Growth | - | - | 59.30 Mn | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 10.32 Mn |
| Sep 30, 2025 | 552,589.00 |
| Jun 30, 2025 | 387,596.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 69,931.00 |
| Sep 30, 2024 | 76,292.00 |
| Jun 30, 2024 | 72,925.00 |
| Mar 31, 2024 | 73,547.00 |
| Dec 31, 2023 | 92,827.00 |
| Sep 30, 2023 | 99,929.00 |
| Jun 30, 2023 | 117,681.00 |
| Mar 31, 2023 | 159,511.00 |
| Dec 31, 2022 | 165,913.00 |
| Sep 30, 2022 | 167,940.00 |
| Jun 30, 2022 | 163,127.00 |
| Mar 31, 2022 | 156,096.00 |
| Dec 31, 2021 | 108,706.00 |
| Sep 30, 2021 | 98,098.00 |
| Jun 30, 2021 | 246,247.00 |